A phase II/III randomized study in advanced non-small cell lung cancer (NSCLC) with first line combination versus sequential gemcitabine and docetaxel: Interim study results No significant financial ...
Three programmed death-1/programmed death-ligand 1 (PD-L1) inhibitors are currently approved for treatment of non–small-cell lung cancer (NSCLC). Treatment with pembrolizumab in NSCLC requires PD-L1 ...
We currently know that COPD, and specifically emphysema, don’t just happen alongside lung cancer; they increase a person’s ...
NEW YORK--(BUSINESS WIRE)--Paige, a global leader in end-to-end digital pathology solutions and clinical AI applications, today announced the availability of Mindpeak’s AI algorithms for IHC biomarker ...
SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (A) (NYSE: A) today announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic indications approvals under EU ...
AZoLifeSciences on MSN
What are the latest advances in cancer research and treatment?
In the 21st century, technology has transformed every aspect of life – from smartphones connecting the world, to social media ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback